First quarter earnings shift Pelagos Insurance Capital into profit
Pelagos Insurance Capital (PLGO) reported a significantly different first quarter in 2026, posting net income of US$108 million compared with a net loss in the same period a year earlier, alongside active share repurchases and higher gross premiums written.
See our latest analysis for Pelagos Insurance Capital.
The stock has rallied strongly in recent months, with a 19.5% year to date share price return and 35.96% 1 year total shareholder return. This suggests momentum has picked up around Pelagos Insurance Capital's earnings recovery, buybacks, and rebrand.
If this shift in sentiment has you looking beyond insurance, it can be a useful time to search for other opportunities across the market using our 19 top founder-led companies
With Pelagos now profitable, buying back stock and trading near its analyst price target, the key question is whether a reported 74% intrinsic discount hints at undervaluation or whether the recent rally already reflects future growth.
Most Popular Narrative: 3.4% Overvalued
The most widely followed narrative pegs Pelagos Insurance Capital's fair value at $22.39, just below the last close at $23.16. This frames a modest valuation premium and sets up a detailed case built on explicit growth and margin assumptions.
The analysts have a consensus price target of $22.39 for Fidelis Insurance Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $27.0, and the most bearish reporting a price target of just $18.0.
Want to see what is baked into that tight valuation range? Revenue, earnings and margins are all carefully mapped out. The real story sits in those projections.
Result: Fair Value of $22.39 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh the risk that large catastrophe losses or prolonged pricing pressure in key lines could weaken margins and unsettle the valuation story.
Find out about the key risks to this Pelagos Insurance Capital narrative.
Another Take: Earnings Multiple Points to Undervaluation
The analyst narrative says Pelagos Insurance Capital looks about 3.4% overvalued versus a fair value of $22.39, but the current P/E of 5.3x tells a different story. That is far below the US Insurance industry at 11.1x, the peer average at 9.4x, and the fair ratio of 10.2x. Together, these figures hint at a wide valuation gap investors need to explain.
To see how this earnings based view stacks up against other methods, check the valuation breakdown in our See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment mixed between a modest premium and a low P/E, it makes sense to move quickly and test the data yourself. To weigh up both the upside potential and the concerns being raised, start with the 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If Pelagos has sharpened your focus, do not stop here. Broaden your watchlist with stocks that match clear, data driven criteria using these targeted screeners.
- Spot potential value opportunities early by scanning companies that currently screen as 51 high quality undervalued stocks.
- Prioritize resilience by focusing on businesses that appear in the solid balance sheet and fundamentals stocks screener (45 results).
- Target steady income prospects by reviewing stocks highlighted in the 13 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com